Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Myriad Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®." Additionally, the Company announced reduced financial guidance for 2025 "reflecting first quarter 2025 results and the current business outlook." Following this news, Myriad stock dropped on heavy trading volume on that day.
In order to be eligible to join the MYGN class action lawsuit, you must have incurred a loss on shares of Myriad Genetics, Inc. purchased during the class period listed above.
TOP
